ERBB2 and triple-negative breast carcinoma: 36) in the luminal group, 7 months (95% CI: 4.31–969) in HER-2-positive group and 5 months (95% CI: 1.83–8.17) in triple-negative breast cancer patients (P=0.364, log-rank test).